Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Ribociclib
Drug: Trametinib
Drug: LXH254
Drug: LTT462

First Posted Date: 2020-06-04

Last Posted Date: 2024-12-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 134

Registration Number: NCT04417621

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 9 locations

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

Phase 2

Terminated

Conditions: Asthma

Interventions: Drug: CSJ117
Drug: Placebo

First Posted Date: 2020-06-01

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 335

Registration Number: NCT04410523

Locations: 🇸🇰
Novartis Investigative Site, Presov, Slovakia

The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.

Phase 1

Completed

Conditions: Liver Disease

Interventions: Drug: triopifexor
Drug: Placebo

First Posted Date: 2020-05-29

Last Posted Date: 2022-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 89

Registration Number: NCT04408937

Locations: 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

Phase 2

Terminated

Conditions: Bronchiectasis

Interventions: Drug: Placebo
Drug: Active drug

First Posted Date: 2020-05-20

Last Posted Date: 2023-08-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT04396366

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Phase 2

Terminated

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Biological: NIS793
Biological: Spartalizumab
Drug: gemcitabine
Drug: nab-paclitaxel

First Posted Date: 2020-05-18

Last Posted Date: 2024-05-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 164

Registration Number: NCT04390763

Locations: 🇺🇸
Beth Israel Deaconess Medical Cente, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

and more 3 locations

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Phase 2

Completed

Conditions: Dry Eye

Interventions: Other: ECF843 vehicle
Drug: ECF843

First Posted Date: 2020-05-18

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 558

Registration Number: NCT04391894

Locations: 🇺🇸
Novartis Investigative Site, Seattle, Washington, United States

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

Phase 2

Completed

Conditions: COVID-19 Pneumonia, Impaired Respiratory Function

Interventions: Drug: MAS825
Other: Placebo
Drug: Standard of Care (SoC)

First Posted Date: 2020-05-11

Last Posted Date: 2022-08-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT04382651

Locations: 🇺🇸
Novartis Investigative Site, Mesquite, Texas, United States

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia

Phase 2

Completed

Conditions: COVID-19 Pneumonia, Impaired Respiratory Function

Interventions: Drug: DFV890
Drug: Standard of Care (SoC)

First Posted Date: 2020-05-11

Last Posted Date: 2022-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 143

Registration Number: NCT04382053

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia

Phase 3

Completed

Conditions: Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

Interventions: Drug: Placebo
Drug: Canakinumab

First Posted Date: 2020-04-27

Last Posted Date: 2022-01-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 454

Registration Number: NCT04362813

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

Phase 3

Completed

Conditions: Cytokine Storm (Covid-19)

Interventions: Drug: Ruxolitinib
Drug: Placebo

First Posted Date: 2020-04-24

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 432

Registration Number: NCT04362137

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy